Antibody molecules that bind to IL-6 receptor

Patent Citations (136)

Non-Patent Literature (208)

• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2009/066590, dated May 10, 2011, 6 pages.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 12/295,039, dated Jun. 28, 2011, 9 pages.Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 12/680,112, dated Oct. 7, 2011, 6 pages.Applicant
• Bartelds et al., “Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis,” Ann Rheum. Dis., 66:921-926 (2007).Applicant
• Bender et al., “Immunogenicity, efficacy and adverse events of adalimumab in RA patients,” Rheumatol. Int., 27:269-274 (2007).Applicant
• Chirino et al., “Minimizing the immunogenicity of protein therapeutics,” Drug Discov. Today., 9:82-90 (2004).Applicant
• Dillon et al., “Structural and functional characterization of disulfide isoforms of the human IgG2 subclass,” J. Biol. Chem., 283:16206-15 (2008).Applicant
• Gessner et al., “The IgG Fc receptor family,” Ann Hematol., 76:231-248 (1998).Applicant
• Ghetie et al., “Increasing the serum persistence of an IgG fragment by random mutagenesis,” Nat. Biotechnol., 15:637-640 (1997).Applicant
• Hinton et al., “An engineered human IgG1 antibody with longer serum half-life,” J. Immunol., 176:346-356 (2006).Applicant
• Hwang et al., “Use of human germline genes in a CDR homology-based approach to antibody humanization,” Methods., 36:35-42 (2005).Applicant
• Ito et al., “The His-probe method: effects of histidine residues introduced into the complementarity-determining regions of antibodies on antigen-antibody interactions at different pH values,” FEBS Lett., 309:85-88 (1992).Applicant
• Johnson et al., “Cation exchange-HPLC and mass spectrometry reveal C-terminal amidation of an IgG1 heavy chain,” Anal. Biochem., 360:75-83 (2007).Applicant
• Jones et al., “Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII,” Thromb. Haemost., 3:991-1000 (2005).Applicant
• Kim et al., “Antibody engineering for the development of therapeutic antibodies,” Mol. Cells, 201:17-29 (2005).Applicant
• Maini et al., “Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate,” Arthritis Rheum., 54:2817-29 (2006).Applicant
• Nishimoto et al., “Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease,” Blood, 106:2627-32 (2005).Applicant
• Nishimoto et al., “Interleukin 6: from bench to bedside,” Nat. Clin. Pract. Rheumatol., 2:619-626 (2006).Applicant
• Onda et al., “Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity,” Cancer Res., 61:5070-77 (2001).Applicant
• Pavlou et al., “The therapeutic antibodies market to 2008,” Eur. J. Pharm. Biopharm., 59:389-396 (2005).Applicant
• Rajpal et al., “A general method for greatly improving the affinity of antibodies by using combinatorial libraries,” Proc. Natl. Acad. Sci. U.S.A., 102:8466-71 (2005).Applicant
• Reichert et al., “Monoclonal antibody successes in the clinic,” Nat. Biotechnol., 23:1073-78 (2005).Applicant
• Rothe et al., “Ribosome display for improved biotherapeutic molecules,” Expert Opin. Biol. Ther., 6:177-187 (2006).Applicant
• Salfeld et al., “Isotype selection in antibody engineering,” Nat. Biotechnol., 25:1369-72 (2007).Applicant
• Sato et al., “Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth,” Cancer Res., 53:851-856 (1993).Applicant
• Shire et al., “Challenges in the development of high protein concentration formulations,” J. Pharm. Sci., 93:1390-1402 (2004).Applicant
• Strand et al., “Biologic therapies in rheumatology: lessons learned, future directions,” Nat. Rev. Drug Discov., 6:75-92 (2007).Applicant
• Van Walle et al., “Immunogenicity screening in protein drug development,” Expert Opin. Biol. Ther., 7:405-418 (2007).Applicant
• Wu et al., “Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract,” J. Mol. Biol., 368:652-665 (2007).Applicant
• International Search Report for App. Ser. No. PCT/JP2009/066590, mailed Oct. 20, 2009, 2 pages.Applicant
• Ohsugi et al., “Success Story of Pre-market Approved Pipeline,” Pharm Stage, 7:13-18 (2007).Applicant
• International Preliminary Report on Patentability for PCT Serial No. PCT/JP2008/067499, dated Apr. 7, 2010, 6 pages.Applicant
• Hanson et al., “Catalytic antibodies and their applications,” Curr. Opin. Biotechnol., 16(6):631-6 (2005).Applicant
• Martin et al., “Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding,” Mol. Cell., 7(4):867-877 (2001).Applicant
• Rathanaswami et al., “Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8,” Biochem. Biophys. Res. Commun., 334(4):1004-13 (2005).Applicant
• Lund et al., “Expression and characterization of truncated forms of humanized L243 IgG1. Architectural features can influence synthesis of its oligosaccharide chains and affect superoxide production triggered through human Fcgamma receptor I,” Eur. J. Biochem., 267(24):7246-57 (2000).Applicant
• CALBIOCHEM ® Buffers, “A guide for the preparation and use of buffers in biological systems,” by Chandra Mohan, Ph.D., Copyright© 2003 EMD Biosciences, Inc., an Affiliate of Merck KGaA, Darmstadt, Germany, 37 pages.Applicant
• Fish & Richardson P.C., Response to Restriction Requirement dated Oct. 12, 2010 in U.S. Appl. No. 12/295,039, filed Apr. 11, 2011, 9 pages.Applicant
• Adams et al., “Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab,” Cancer Immunol. Immunother., 55:717-727 (2006).Applicant
• Binz et al., “Engineering novel binding proteins from nonimmunoglobulin domains,” Nat. Biotechnol., 23:1257-68 (2005).Applicant
• Branden and Tooze, “Recognition of Foreign Molecules by the Immune System,” Introduction to Protein Structure, 2d Ed., Garland Publishing, pp. 299-323 (1999).Applicant
• Carter, “Bispecific human IgG by design,” J. Immunol. Methods, 248:7-15 (2001).Applicant
• Comper and Glasgow, “Charge selectivity in kidney ultrafiltration,” Kidney Int., 47:1242-51 (1995).Applicant
• Couto et al., “Anti-BA46 monoclonal antibody Mc3: humanization using a novel positional consensus and in vivo and in vitro characterization,” Cancer Res., 55:1717-22 (1995).Applicant
• Deen et al., “Structural determinants of glomerular permeability,” Am. J. Physiol. Renal. Physiol., 281:F579-F596 (2001).Applicant
• Del Rio et al., “An engineered penicillin acylase with altered surface charge is more stable in alkaline pH,” Ann. NY Acad. Sci., 799:61-64 (1996).Applicant
• Ewert et al., “Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering,” Methods, 34:184-199 (2004).Applicant
• Ghetie and Ward, “FcRn: the MHC class I-related receptor that is more than an IgG transporter,” Immunol. Today, 18:592-598 (1997).Applicant
• Ghetie et al., “Multiple roles for the major histocompatibility complex class I- related receptor FcRn,” Annu. Rev. Immunol., 18:739-766 (2000).Applicant
• Gobburu et al., “Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys,” J. Pharmacol. Exp. Ther., 286:925-930 (1998).Applicant
• Goode et al., “The glomerular basement membrane charge-selectivity barrier: an oversimplified concept?” Nephrol. Dial. Transplant., 11:1714-16 (1996).Applicant
• Graves et al., “Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody,” Clin. Cancer Res., 5:899-908 (1999).Applicant
• Gupta et al., “Affinity chromatography and co-chromatography of bispecific monoclonal antibody immunoconjugates,” J. Biochem. Biophys. Methods, 51:203-216 (2002).Applicant
• He et al., “Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P-selectin,” J. Immunol., 160:1029-35 (1998).Applicant
• Kashmiri et al., “Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49,” Hybridoma, 14:461-473 (1995).Applicant
• Khawli et al., “Improved tumor localization and radioimaging with chemically modified monoclonal antibodies,” Cancer Biother. Radiopharm., 11:203-215 (1996).Applicant
• Kim et al., “Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-tac monoclonal antibody labeled with 99mTc,” Bioconjugate Chem., 10:447-453 (1999).Applicant
• Kim et al., “Lowering of pI by acylation improves the renal uptake of 99mTc-labeled anti-Tac dsFv: effect of different acylating reagents,” Nucl. Med. Biol., 29:795-801 (2002).Applicant
• Kobayashi et al., “The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points,” Cancer Res., 59:422-430 (1999).Applicant
• Kreutz et al., “Efficient bispecific monoclonal antibody purification using gradient thiophilic affinity chromatography,” J. Chromatogr. B, 714:161-170 (1998).Applicant
• Lindhofer et al., “Preferential Species-Restricted Heavy/Light Chain Pairing in Rat/Mouse Quadromas,” J. Immunol., 155:219-225 (1995).Applicant
• Lobo et al., “Antibody pharmacokinetics and pharmacodynamics,” J. Pharm. Sci., 93:2645-68 (2004).Applicant
• Manzke et al., “Single-step purification of bispecific monoclonal antibodies for immnunotherapeutic use by hydrophobic interaction chromatography,” J. Immunol. Methods, 208:65-73 (1997).Applicant
• Marvin et al., “Recombinant approaches to IgG-like bispecific antibodies,” Acta. Pharmacol. Sin., 26:649-658 (2005).Applicant
• Marvin et al., “Redesigning an antibody fragment for faster association with its antigen,” Biochemistry, 42:7077-83 (2003).Applicant
• Merchant et al., “An efficient route to human bispecific IgG,” Nat. Biotechnol., 16:677-681 (1998).Applicant
• Pavlinkova et al., “Charge-modified single chain antibody constructs of monoclonal antibody CC49: Generation, characterization, pharmacokinetics, and biodistribution analysis,” Nucl. Med. Biol., 26:27-34 (1999).Applicant
• Poduslo et al., “Polyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers,” J. Neurochem., 66:1599-1609 (1996).Applicant
• Sal-Man et al., “Arginine mutations within a transmembrane domain of Tar, an Escherichia coli aspartate receptor, can drive homodimer dissociation and heterodimer association in vivo,” Biochem. J., 385:29-36 (2005).Applicant
• Schaeffer et al., “The rat glomerular filtration barrier does not show negative charge selectivity,” Microcirculation, 9:329-342 (2002).Applicant
• Segal et al., “Bispecific antibodies in cancer therapy,” Curr. Opin. Immunol., 11:558-562 (1999).Applicant
• Shaul, “Exploring the charge space of protein-protein association: a proteomic study,” Proteins, 60:341-352 (2005).Applicant
• Shields et al., “High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R,” J. Biol. Chem., 276:6591-6604 (2001) (Epub Nov. 28, 2000).Applicant
• Tarditi et al., “Selective high-performance liquid chromatographic purification of bispecific monoclonal antibodies,” J. Chromatogr., 599:13-20 (1992).Applicant
• Ten Kate et al., “Effect of isoelectric point on biodistribution and inflammation: imaging with indium-111-labelled IgG,” Eur. J. Nucl. Med., 17:305-309 (1990).Applicant
• Tsurushita et al., “Design of humanized antibodies: From anti-Tac to Zenapax,” Methods, 36:69-83 (2005).Applicant
• Yamasaki et al., “Pharmacokinetic analysis of in vivo disposition of succinylated proteins targeted to liver nonparenchymal cells via scavenger receptors: importance of molecular size and negative charge density for in vivo recognition by receptors,” J. Pharmacol. Exp. Ther., 301:467-477 (2002).Applicant
• Yang et al., “Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation,” Protein Eng., 16:761-770 (2003).Applicant
• Zuckier et al., “Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life,” Cancer Res., 58:3905-08 (1998).Applicant
• International Search Report for App. Ser. No. PCT/JP2008/067534, mailed Oct. 21, 2008, 4 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2008/067534, dated Apr. 7, 2010, 7 pages.Applicant
• International Search Report for App. Ser. No. PCT/JP2009/057309, mailed Jul. 7, 2009, 8 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2009/057309, mailed Nov. 30, 2010, 7 pages.Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 12/295,039, dated Oct. 12, 2010, 9 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2007/057036, dated Oct. 21, 2008, 6 pages.Applicant
• International Search Report for App. Ser. No. PCT/JP2007/057036, dated May 1, 2007, 2 pages.Applicant
• European Search Report for App. Ser. No. 07 74 0494, dated Sep. 3, 2009, 3 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2007/057058, dated Oct. 21, 2008, 11 pages.Applicant
• International Search Report App. Ser. No. PCT/JP2007/057058, mailed May 7, 2001, 2 pages.Applicant
• European Search Report for App. Ser. No. 07 74 0474, dated Mar. 16, 2009, 5 pages.Applicant
• Fish & Richardson P.C., Amendment and Response to Species Election Requirement dated Oct. 7, 2011 in U.S. Appl. No. 12/680,112, filed Dec. 6, 2011, 15 pages.Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 12/936,587, dated Dec. 6, 2011, 7 pages.Applicant
• Dall'Acqua et al., “Antibody humanization by framework shuffling,” Methods, 36(1):43-60 (2005).Applicant
• Fish & Richardson P.C., Amendment in Reply to Action dated Jun. 28, 2011 in U.S. Appl. No. 12/295,039, filed Dec. 27, 2011, 14 pages.Applicant
• Tsuchiya, Credit Suisse Seminar, “Therapeutic Antibody,” at Fuji-Gotemba Laboratories, p. 21 (2006).Applicant
• Algonomics—Tripole® applications [online] [retrieved on Feb. 29, 2012]. Retrieved from the Internet: http://web.archive.org/web20090221052902/http://www.algonomics.com/proteinengineering/tripole —applications.php, 2 pages. (Feb. 21, 2009).Applicant
• Almagro et al., “Humanization of antibodies,” Front Biosci., 13:1619-33 (2008).Applicant
• Armour et al., “Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities,” Eur. J. Immunol., 29(8):2613-24 (1999).Applicant
• Chau et al., “HuM291(Nuvion), a humanized Fc receptor-nonbinding antibody against CD3, anergizes peripheral blood T cells as partial agonist of the T cell receptor,” Transplantation., 71(7):941-50 (2001).Applicant
• Chen et al., “Generation and analysis of random point mutations in an antibody CDR2 sequence: many mutated antibodies lose their ability to bind antigen,” J. Exp. Med., 176(3):855-66 (1992).Applicant
• Chen et al., “Defective secretion of an immunoglobulin caused by mutations in the heavy chain complementarity determining region 2,” J. Exp. Med., 180(2):577-86 (1994).Applicant
• Chu et al., “Accumulation of succinimide in a recombinant monoclonal antibody in mildly acidic buffers under elevated temperatures,” Pharm. Res., 24(6):1145-56 (2007).Applicant
• Cole et al., “Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells,” J. Immunol., 159(7):3613-21 (1997).Applicant
• Cordoba et al., “Non-enzymatic hinge region fragmentation of antibodies in solution,” J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 818(2):115-21 (2005).Applicant
• Damschroder et al., “Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties,” Mol. Immunol., 44(11):3049-60 (2007).Applicant
• De Groot et al., “De-immunization of therapeutic proteins by T-cell epitope modification,”Dev. Biol. (Basel), 122:171-94 (2005).Applicant
• Fujii, “Antibody affinity maturation by random mutagenesis,” Methods Mol. Biol., 248:345-59 (2004).Applicant
• Gerstner et al., “Sequence plasticity in the antigen-binding site of a therapeutic anti-HER2 antibody,” J. Mol. Biol., 321(5):851-62 (2002).Applicant
• Guyre et al., “Increased potency of Fc-receptor-targeted antigens,” Cancer Immunol. Immunother., 45(3-4):146-8 (1997).Applicant
• Hanes et al., “Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display,” Nat. Biotechnol., 18(12):1287-1292 (2000).Applicant
• Hinton et al., “Engineered human IgG antibodies with longer serum half-lives in primates,” J. Biol. Chem., 279(8):6213-6 (2004).Applicant
• Igawa et al., “Engineering the variable region of therapeutic IgG antibodies,” MAbs, 3(3):243-52 (2011).Applicant
• Igawa et al., “Reduced elimination of IgG antibodies by engineering the variable region,” Protein Eng. Des. Sel., 23(5):385-92 (2010).Applicant
• Katayose et al., “MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth,” Cancer Res., 56(18):4205-12 (1996).Applicant
• Komissarov et al., “Site-specific mutagenesis of a recombinant anti-single-stranded DNA Fab. Role of heavy chain complementarity-determining region 3 residues in antigen interaction,” J. Biol. Chem., 272(43):26864-70 (1997).Applicant
• Leong et al., “Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation,” Cytokine, 16(3):106-19 (2001).Applicant
• Liu et al., “Heterogeneity of monoclonal antibodies,” J. Pharm. Sci., 97(7):2426-47 (2008).Applicant
• Maeda et al., “pH-dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes,” J. Control Release, 82(1):71-82 (2002).Applicant
• Martinez et al., “Disulfide connectivity of human immunoglobulin G2 structural isoforms,” Biochemistry, 47(28):7496-7508 (2008).Applicant
• Maxfield et al., “Endocytic recycling,” Nat. Rev. Mol. Cell Biol., 5(2):121-32 (2004).Applicant
• Murtaugh et al., “A combinatorial histidine scanning library approach to engineer highly pH-dependent protein switches,” Protein Sci., 20(9):1619-31 doi:10.1002/pro 696 (2011).Applicant
• Nesterova et al., “Glypican-3 as a novel target for an antibody-drug conjugate,” AACR Abstract No. 656, Los Angeles, CA (Apr. 4-18, 2007).Applicant
• Ono et al., “The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity,” Mol. Immunol., 36(6):387-95 (1999).Applicant
• Pardridge et al., “Enhanced endocytosis in cultured human breast carcinoma cells and in vivo biodistribution in rats of a humanized monoclonal antibody after cationization of the protein,” J. Pharmacol. Exp. Ther., 286(1):548-54 (1998).Applicant
• Pons et al., “Energetic analysis of an antigen/antibody interface: alanine scanning mutagenesis and double mutant cycles on the HyHEL-10/lysozyme interaction,” Protein Sci., 8(5):958-68 (1999).Applicant
• Presta, “Engineering of therapeutic antibodies to minimize immunogenicity and optimize function,” Adv. Drug Deliv. Rev., 58(5-6):640-56 (2006).Applicant
• Reddy et al., “Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4,” J. Immunol., 164(4):1925-33 (2000).Applicant
• Reichert et al., “Development trends for monoclonal antibody cancer therapeutics,” Nat. Rev. Drug Discov., 6(5):349-56 (2007).Applicant
• Schmitz et al., “Phage display: a molecular tool for the generation of antibodies—a review,” Placenta., 21 Suppl A:S106-12 (2000).Applicant
• Tan et al., “Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility,” Immunotechnology, 4(2):107-114 (1998).Applicant
• Teeling et al., “The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20,” J Immunol., 177(1):362-71 (2006).Applicant
• Vaisitti et al., “Cationization of monoclonal antibodies: another step towards the “magic bullet”?,” J. Biol. Regul. Homeost. Agents., 19(3-4):105-12 (2005).Applicant
• Wang et al., “Polyethylene Glycol-modified Chimeric Toxin Composed of Transforming Growth Factor alpha and Pseudomonas Exotoxin,” Cancer. Res., 53:4588-4594 (1993).Applicant
• Wiens et al., “Somatic mutation in VH complementarity-determining region 2 and framework region 2: differential effects on antigen binding and Ig secretion,” J. Immunol., 159(3):1293-302 (1997).Applicant
• Wiens et al., “Mutation of a single conserved residue in VH complementarity-determining region 2 results in a severe Ig secretion defect,” J. Immunol., 167(4):2179-86 (2001).Applicant
• Wypych et al., “Human IgG2 antibodies display disulfide-mediated structural isoforms,” J. Biol. Chem., 283(23):16194-16205 (2008).Applicant
• Xiang et al., “Study of B72.3 combining sites by molecular modeling and site-directed mutagenesis,” Protein Eng., 13(5):339-44 (2000).Applicant
• Zwick et al., “The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5,” J. Virol., 78(6):3155-61 (2004).Applicant
• USPTO Non Final Office Action in U.S. Appl. No. 12/680,112, dated Feb. 29, 2012, 8 pages.Applicant
• European Search Report for App. Ser. No. EP 09 72 9337, dated Nov. 3, 2011, 3 pages.Applicant
• USPTO Final Office Action in U.S. Appl. No. 12/295,039, dated Apr. 12, 2012, 8 pages.Applicant
• Fish & Richardson P.C., Third Preliminary Amendment and Response to Restriction Requirement dated Dec. 6, 2011 in U.S. Appl. No. 12/936,587, filed Jun. 5, 2012, 7 pages.Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 12/680,082, dated Jun. 6, 2012, 12 pages.Applicant
• Chien et al., “Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: proposal of a structural mechanism,” Proc. Natl. Acad. Sci. U.S.A., 86(14):5532-6 (1989).Applicant
• Choy et al., “Inhibiting interleukin-6 in rheumatoid arthritis,” Curr. Rheumatol. Rep., 10(5):413-7 (2008).Applicant
• Davies et al., “Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding,” Immunotechnology, 2(3):169-79 (1996).Applicant
• De Pascalis et al., “Grafting of “abbreviated” complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody,” J. Immunol., 169(6):3076-84 (2002).Applicant
• Guerne et al., “Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis,” J. Clin. Invest., 83(2):585-92 (1989).Applicant
• Hirano et al., “Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis,” Eur. J. Immunol., 18(11):1797-801 (1988).Applicant
• Holt et al., “Domain antibodies: proteins for therapy,” Trends Biotechnol., 21(11):484-90 (2003).Applicant
• Houssiau et al., “Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides,” Arthritis Rheum., 31(6):784-8 (1988).Applicant
• Igawa et al., “Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization,” Nat. Biotechnol., 28(11):1203-7 (2010).Applicant
• Kishimoto, “The biology of interleukin-6,” Blood, 74(1):1-10 (1989).Applicant
• Kotake et al., “Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation,” J. Bone Miner Res., 11(1):88-95 (1996).Applicant
• Madhok et al., “Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity,” Ann. Rheum. Dis., 52(3):232-4 (1993).Applicant
• Maynard et al., “Antibody engineering,” Annu. Rev. Biomed. Eng., 2:339-76 (2000).Applicant
• Nishimoto, Nihon Rinsho, 65(7):1218-26 (2007) (with English translation).Applicant
• Pini et al., “Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel,” J. Biol. Chem., 273(34):21769-76 (1998).Applicant
• Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. U.S.A., 79(6):1979-83 (1982).Applicant
• Sack et al., “Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis,” Rheumatol. Int., 13(2):45-51 (1993).Applicant
• Tamura et al., “Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6,” Proc. Natl. Acad. Sci. USA, 90(24):11924-8 (1993).Applicant
• Vajdos et al., “Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis,” J. Mol. Biol., 320(2):415-28 (2002).Applicant
• Wu et al., “Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues,” J. Mol. Biol., 294(1):151-62 (1999).Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 12/936,587, dated Jun. 25, 2012, 5 pages.Applicant
• Fish & Richardson P.C., Response to Species Election Requirement dated Jun. 25, 2012 in U.S. Appl. No. 12/936,587, filed Jul. 25, 2012, 1 page.Applicant
• Fish & Richardson P.C., Fourth Preliminary Amendment and Response to Restriction Requirement dated Jun. 6, 2012 in U.S. Appl. No. 12/680,082, filed Jun. 29, 2012, 13 pages.Applicant
• Fish & Richardson P.C., Amendment in Reply to Action of Feb. 29, 2012 in U.S. Appl. No. 12/680,112, filed Aug. 27, 2012, 12 pages.Applicant
• Fish & Richardson P.C., Amendment in Reply to Action dated Apr. 12, 2012 in U.S. Appl. No. 12/295,039, filed Sep. 11, 2012, 12 pages.Applicant
• Dall'Acqua et al., “Modulation of the effector functions of a human IgG1 through engineering of its hinge region,” J. Immunol., 177(2):1129-38 (2006).Applicant
• Elliott et al., “Activation of the erythropoietin (EPO) receptor by bivalent anti-EPO receptor antibodies,” J. Biol. Chem., 271(40):24691-7 (1996).Applicant
• Kai et al., “Switching constant domains enhances agonist activities of antibodies to a thrombopoietin receptor,” Nat. Biotechnol., 26(2):209-11 (2008).Applicant
• Kobayashi et al., “A monoclonal antibody specific for a distinct region of hen egg-white lysozyme,” Mol. Immunol., 19:619-30 (1982).Applicant
• Ohno et al., “Antigen-binding specificities of antibodies are primarily determined by seven residues of VH,” Proc. Natl. Acad. Sci. U.S.A., 82(9):2945-9 (1985).Applicant
• Ozhegov et al., Tolkovyi Slovar Russkogo iazyka: 2004, p. 292 (with an English translation of the corresponding part only).Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 12/680,112, dated Sep. 19, 2012, 6 pages.Applicant
• Fish & Richardson P.C., Amendment and Reply to Restriction Requirement dated Sep. 19, 2012 in U.S. Appl. No. 12/680,112, filed Oct. 17, 2012, 13 pages.Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 12/680,082, dated Sep. 14, 2012, 6 pages.Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 12/679,922, dated Oct. 2, 2012, 9 pages.Applicant
• Bayry et al , “Immuno affinity purification of foot and mouth disease virus type specific antibodies using recombinant protein adsorbed to polystyrene wells,” J. Virol. Methods, 81:21-30 (1999).Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 12/936,587, dated Nov. 7, 2012, 13 pages.Applicant
• Fish & Richardson P.C., Amendment and Response to Election Requirement dated Sep. 14, 2012 in U.S. Appl. No. 12/680,082, filed Nov. 8, 2012, 14 pages.Applicant
• Fish & Richardson P.C., Response to Restriction Requirement dated Oct. 2, 2012 in U.S. Appl. No. 12/679,922, filed Nov. 1, 2012, 2 pages.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 13/595,139, dated Nov. 14, 2012, 10 pages.Applicant
• USPTO Restriction Requirement in U.S. Appl. No. 13/257,145, dated Mar. 20, 2013, 11 pages.Applicant
• USPTO Restriction in U.S. Appl. No. 13/524,528, dated Mar. 21, 2013, 7 pages.Applicant
• Brown et al., “Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR2: a means of minimizing B cell wastage from somatic hypermutation?, ”J. Immunol., 156(9):3285-91 (1996).Applicant
• Deng et al., “An Agonist Murine Monoclonal Antibody to the Human c-Mpl Receptor Stimulates Megakaryocytopoiesis,” Blood, 92:1981-88 (1998).Applicant
• MacCallum et al., “Antibody-antigen interactions: contact analysis and binding site topography,” J. Mol. Biol., 262:732-45 (1996).Applicant
• Sun et al., “Coexpression of Gas6/Axl in human ovarian cancers,” Oncology, 66(6):450-7 (2004).Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 12/679,922, dated Jan. 3, 2013, 25 pages.Applicant
• USPTO Non Final Office Action in U.S. Appl. No. 12/680,112, dated Feb. 4, 2013, 9 pages.Applicant
• USPTO Non-Final Office Action U.S. Appl. No. 12/680,082, dated Feb. 14, 2013, 12 pages.Applicant
• Presta et al., “Molecular engineering and design of therapeutic antibodies,” Curr. Opin. Immunol., 20(4):460-70. doi. 10.1016/j.coi.2008.06.012 (2008).Applicant
• Amersham Biosciences, “Affinity Chromatography: Principles and Methods,” Edition AD, pp. 16-18, 137 (2002).Applicant
• Zhu et al., “MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells,” J. Immunol., 166(5):3266-76 (2001).Applicant
• Nishimoto et al., “Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan” Clin. Rev. Allergy Immunol., 28(3):221-30 (2005).Applicant
• Roitt et al., Immunology, M. Mir, p. 110 (2000) (with English translation).Applicant
• Yokota et al., “Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis,” Clin. Rev. Allergy Immunol., 28(3):231-8 (2005).Applicant
• Allen et al., “Interchain disulfide bonding in human IgG2 antibodies probed by site-directed mutagenesis,” Biochemistry, 48(17):3755-66 (2009).Applicant
• Mihara et al., “Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family,” Int. Immunopharmacol., 5(12):1731-40 (2005).Applicant
• Nishimoto et al., “Hummanized antihuman IL-6 receptor antibody, tocilizumab,” Handb Exp Pharmacol., (181):151-60 (2008).Applicant
• Nishimoto et al., “Anti-interleukin 6 receptor antibody treatment in rheumatic disease,” Ann Rheum Dis., 59 Suppl 1:i21-7 (2000).Applicant
• Fish & Richardson P.C., Preliminary Amendment and Response to Restriction Requirement dated Mar. 20, 2013 in U.S. Appl. No. 13/257,145, filed Apr. 22, 2013, 7 pages.Applicant
• Fish & Richardson P.C., Amendment in Reply to Office Action dated Nov. 14, 2012 in U.S. Appl. No. 13/595,139, filed May 14, 2013, 19 pages.Applicant
• Fish & Richardson P.C., Amendment in Reply to Action dated Jan. 3, 2013 in U.S. Appl. No. 12/679,922, filed Jul. 2, 2013, 18 pages.Applicant
• USPTO Non-Final Office Action in U.S. Appl. No. 13/257,145, dated Jul. 2, 2013, 20 pages.Applicant
• Rich et al., “Grading the commercial optical biosensor literature-Class of 2008: ‘The Mighty Binders’, ” J. Mol. Recognit., 23(1):1-64(2010). doi: 10.1002/jmr.1004.Applicant
• Yang et al., “CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range,” J. Mol. Biol., 254(3):392-403 (1995).Applicant